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Summary
Objectives: Nosocomial Gram-negative bacteremia in the critically ill is associated with sig-
nificant morbidity and mortality. This study provides epidemiological and antimicrobial suscept-
ibility data for nosocomial Gram-negative bacteremia in a general intensive care unit (ICU) over a
five-year period.
Methods: Positive blood cultures from January 1, 1999 to December 31, 2003 were reviewed for
microbial etiology and susceptibilities. Patient charts were reviewed to determine the source of
infection and outcome.
Results: Forty-five nosocomial Gram-negative bacteremias occurred in 44 patients. Infection
rates of 6.9/1000 admissions and 11.3/10 000 patient days remained stable. Admitting diagnoses
included respiratory failure, solid organ transplant, post-surgery, and multi-trauma. Seven
bacterial species were identified; Pseudomonas aeruginosa and Enterobacter spp were most
common. Sources of bacteremia included pneumonia (48.9%), and central venous catheterization
(22.2%). Antimicrobial susceptibilities were highest for imipenem, gentamicin, tobramycin,
ceftazidime, and piperacillin—tazobactam. Ciprofloxacin susceptibility was inferior to imipenem,
gentamicin, and tobramycin (p < 0.05). Mortality rates were 53.3% in the ICU, and 60% for overall
hospitalization. Average length of ICU stay was 50.5 days compared to 6.13 days for all-comers.
Conclusions: Nosocomial Gram-negative bacteremia is associated with marked morbidity and
mortality in critically ill patients. Significant resistance to ciprofloxacin was demonstrated.
Empiric treatment regimens should be based on unit-specific data.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.* Corresponding author. Tel.: +1 780 407 7786; fax: +1 780 407 7137.
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1201-9712/$32.00 # 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2005.07.003
Nosocomial Gram-negative bacteremia in an ICU 321Introduction
Nosocomial bacteremia is a major subgroup of hospital-
acquired infections. Gram-negative bacteremia, in particu-
lar, is associated with significant morbidity and mortality.1
Studies of Gram-negative bacteremia provide epidemiologi-
cal data, and may improve empiric antimicrobial therapy
based on local patterns of susceptibility. Such information
may also lead to infection control measures designed to
decrease infection rates.
Intensive care unit (ICU) patients are at higher risk of
developing nosocomial infections when compared with other
hospitalized patients.2,3 Incidence of nosocomial bacteremia
in ICU patients has been reported from 1% to as high as 6.5%,
compared to 0.65% in other hospitalized patients.4,5 Further-
more, a recent epidemiologic study showed that ICU patients
represented 34% of all hospital Gram-negative bacteremias.6
Patients with Gram-negative bacteremia have a high mor-
tality rate. In a study from a large Swiss university hospital,
there was a 7-fold higher death rate compared to hospita-
lized patients without Gram-negative bacteremia.7 In addi-
tion, Gram-negative bacteremia in the setting of critical
illness, as determined by admission to ICU, has been asso-
ciated with higher mortality rates and prolonged ICU stay.7,8
The mortality rate in a study of Gram-negative sepsis in five
ICUs in Taipei was 36.1%, with 77.4% of all deaths directly
related to the bloodstream infection.1 Furthermore, Gram-
negative bacteremias have been associated with higher case
fatality rates when compared to Gram-positive bacteremias
(44% vs. 30%).9 In short, Gram-negative bacteremia has a
significant impact on patient mortality, morbidity, and
resource utilization.
The purpose of this study is to provide up-to-date data on
the frequency, source, microbial etiology, and susceptibil-
ities of Gram-negative bacteremia, with the goal of improv-
ing its management. This is the first Canadian study of
nosocomial Gram-negative bacteremia in a general ICU,
and we hope to emphasize the importance of frequent
surveillance for both nosocomial infections and increasing
antimicrobial resistance.
Methods
The University of Alberta Hospital is a 700-bed tertiary
referral hospital in Edmonton, Canada. It is the principal
teaching hospital of the University of Alberta, Faculty of
Medicine. It is a level-one trauma center, and has a referral
area of over twomillion people. It includes a 29-bed adult ICU
that admits general medical, trauma, and surgical patients,
as well as solid organ transplant recipients. The ICU provides
invasive hemodynamic monitoring and support, mechanical
ventilation, and continuous renal replacement therapy.
Under usual circumstances, cardiovascular surgery, neuro-
surgical/neurological, and burn patients requiring intensive
care are not admitted to the general unit, as there are
separate dedicated ICUs for these patients.
Inpatient populations have been prospectively surveyed
for nosocomial bloodstream infections since 1986 as part of
our hospital’s routine infection control surveillance program.
Positive blood cultures in ICU patients are identified by the
clinical microbiology laboratory (BACTEC 9240 Blood CultureSystem; Becton Dickinson Biosciences) and reviewed daily.
Charts are reviewed and the blood culture isolates are
categorized as contaminated specimens, community-
acquired infections, or nosocomial bacteremias using stan-
dardized criteria. Originating sources for nosocomial bacter-
emias are then identified according to standard CDC
definitions.10
All cases of aerobic Gram-negative bacteremia from
January 1, 1999 to December 31, 2003 were reviewed.
Demographic data, time from admission to bacteremia,
causative organisms, antimicrobial susceptibilities, choice
of empiric antibiotic therapy, ICU length of stay, and mor-
tality rates were collected. For statistical analysis, differ-
ences in proportions for categorical variables were
compared using the Chi-square test; for continuous variables
the t-test was used.
Results
There were 6544 admissions to the general systems ICU from
January 1, 1999 to December 31, 2003. Forty-five episodes of
Gram-negative nosocomial bacteremia occurred in 44
patients, resulting in infection rates of 6.9 per 1000 ICU
admissions and 11.3 per 10 000 patient days. Annual infection
rates by year fluctuated from 3.0 to 11.1 per 1000 admissions
and 4.9 to 19.2 per 10 000 patient days, with no overall
increase in rates over the five-year period. The majority
(95.6%) of bloodstream infections were monomicrobial, with
only one episode of polymicrobial bacteremia. This polymi-
crobial bacteremia was analyzed as if it were two separate
infections. The mean patient age was 55.3 years (range 17—
86 years); 27.3% of patients were female, and 72.7% were
male.
Admitting diagnoses included: respiratory failure (18.2%),
post-surgery (15.9%; all were cancer-related surgeries), solid
organ transplant (15.9%), multi-trauma (13.6%), hepatic fail-
ure (9.1%), intra-abdominal sepsis (9.1%), other sepsis (6.8%),
decreased level of consciousness (4.5%), and other (6.8%,
with one case each of gastrointestinal bleed, acute renal
failure, and complications following burns). Ten patients
(22.7%) were on corticosteroids or other immunosuppressive
agents prior to admission to ICU (Table 1).
Sources of bacteremia (Table 2) included pneumonia
(48.9% all but two of which were ventilator-associated),
central venous catheter (22.2%), surgical site (15.6%), gas-
trointestinal (6.7%), skin (4.4%), and urinary tract infection
(2.2%). There were no cases of primary bacteremia, or
associations with ear/nose/throat infections or gastrointest-
inal endoscopy. Of the ten bacteremias due to central line
infections, femoral catheters were used in five (50%), sub-
clavian catheters in three (30%), and internal jugular cathe-
ters in two of the cases (20%).
Seven bacterial genera were identified in the 45 episodes
of bacteremia (Table 2). These were Pseudomonas aerugi-
nosa (22.2%), Enterobacter spp (22.2%; nine E. cloacae, one
E. aerogenes), Klebsiella pneumoniae (17.8%), Escherichia
coli (15.6%), Serratia marcescens (11.1%), Stenotrophomo-
nas maltophilia (8.9%), and Acinetobacter anitratus (2.2%).
Two patients had two strains of the same species; during our
analysis these were analyzed separately for susceptibility
data but included as only one episode of bacteremia.
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Table 1 Demographic and clinical data
No. (%)
Total ICU admissions 6544
Episodes of bacteremia 45
Monomicrobial bacteremia 43 (95.6)
Infection rate per 10 000 ICU
patient days, total
11.3
1999 10.1
2000 19.2
2001 14.7
2002 8.1
2003 4.9
Mean patient age (years) 55.3
Male gender 32 (72.7)
Admitting diagnoses
Respiratory failure 8 (18.2)
Post-surgical 7 (15.9)
Solid organ transplant 7 (15.9)
Multi-trauma 6 (13.6)
Hepatic failure 4 (9.1)
Intra-abdominal sepsis 4 (9.1)
Other sepsis 3 (6.8)
Decreased level of consciousness 2 (4.5)
Other 3 (6.8)
Corticosteroid use prior to admission 10 (22.7)Overall susceptibilities are shown in Table 3. Of the iso-
lates, 98.5% were susceptible to imipenem, 94.6% to genta-
micin, 93.3% to tobramycin, 92.4% to ceftazidime, 88.9% to
piperacillin—tazobactam, 73.2% to ciprofloxacin, 72.0% to
trimethoprim—sulfamethoxazole (TMP—SMX), and 62.1% to
piperacillin alone. Imipenem, tobramycin, and gentamicin
were superior to ciprofloxacin ( p values 0.0013, 0.0045, and
0.0055, respectively), with a trend towards ceftazidime and
piperacillin—tazobactam superiority that was not statisti-
cally significant ( p values 0.064 and 0.12, respectively).
There was also a trend towards imipenem superiority com-
pared to piperacillin—tazobactam, but this was not statisti-
cally significant ( p = 0.11).
All four strains of Stenotrophomonas maltophilia were
susceptible to TMP—SMX, and resistant to ticarcillin—clavu-
lanate, minocycline, and amikacin. None of these patients
received initial empiric therapy with TMP—SMX, but all were
treated with TMP—SMX once susceptibilities were reported.Table 2 Microorganisms isolated by source
Organism Site
PN CVC
Pseudomonas aeruginosa 7 2
Enterobacter spp 6 1
Klebsiella pneumoniae 4 2
Escherichia coli 1 0
Serratia marcescens 3 1
Stenotrophomonas maltophilia 0 4
Acinetobacter anitratus 1 0
Total (%) 22 (48.9) 10 (22.2)
PN: pneumonia; CVC: central venous catheter; SSI: surgical site infectData were collected on the choice of empiric therapy after
preliminary Gram-stain results were known. Three patients
were not treated due to compassionate care limitations. For
one episode, susceptibility of the organism to the empiric
antibiotic was not tested. After excluding these four epi-
sodes, 80.5% of bacteremias were treated with an agent to
which the microorganism was ultimately susceptible. After
excluding the four cases of Stenotrophomonas maltophilia,
for which empiric therapy is currently not standard of care,
empiric coverage increased to 89.2%.
ICU length of stay and median time to bacteremia was
calculated for all patients. If there were multiple ICU
admissions, the discrete ICU admission surrounding the
bacteremia was used. In three cases, multiple transfers
to and from the ICU meant that no discrete ICU admission
could be identified. As such, the entire hospitalization was
counted. The median time from admission to hospital to
development of bacteremia was 18.5 days (mean 32.9 days,
95% confidence interval (CI) 0—100.9), and time from
admission to ICU was 15.0 days (mean 26.0 days, 95% CI
0—90.1). The median length of stay for study patients was
39.0 days (mean 50.5 days, 95% CI 0—150.1). In comparison,
the median length of stay for all-comers to the ICU over the
same five-year period was 6.16 days (mean 6.13 days, 95% CI
4.29—7.97).
Mortality rates for patients with nosocomial Gram-nega-
tive bacteremia were 53.3% in the ICU and 60% over the
entire hospitalization. This compares to an overall mortality
rate of 11.72% for the year 2004 in our ICU patients (five-year
data were not available). After excluding cases of Stenotro-
phomonas, when empiric antimicrobial therapy was appro-
priate, the mortality rate over the entire hospitalization was
59.4%. When empiric therapy was not effective, requiring a
change of therapy after susceptibilities were reported, mor-
tality was 100%. Median lengths of stay were 41 and 69 days,
respectively, for those who did and did not receive appro-
priate empiric therapy.
Discussion
This prospective cohort study presents important data on
nosocomial aerobic Gram-negative bacteremia in an adult
general systems ICU over a five-year period. The majority of
bacteremias were monomicrobial infections. Annual infec-
tion rates ranged from 3.0 to 11.1 per 1000 admissions and
4.9 to 19.2 per 10 000 patient days, higher than previouslyTotal (%)
SSI GI Skin UTI
1 0 0 0 10 (22.2)
1 1 1 0 10 (22.2)
0 1 1 0 8 (17.8)
4 1 0 1 7 (15.6)
1 0 0 0 5 (11.1)
0 0 0 0 4 (8.9)
0 0 0 0 1 (2.2)
7 (15.6) 3 (6.7) 2 (4.4) 1 (2.2) 45 (100)
ion; GI: gastrointestinal; UTI: urinary tract infection.
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Table 3 Antimicrobial susceptibility of blood culture isolates
Agent Antimicrobial susceptibility by organism (%)
Pseudomonas
n = 11
Enterobacter
n = 11
Klebsiella
n = 8
E. coli
n = 7
Serratia
n = 5
Acinetobacter
n = 1
Total
n = 43
Ceftazidime 81.8 72.7 100 100 100 100 92.4
Ciprofloxacin 54.5 90.9 62.5 71.4 60 100 73.2
Gentamicin 81.8 100 100 85.7 100 100 94.6
Imipenem 90.9 100 100 100 100 100 98.5
Piperacillin 81.8 72.7 75 42.9 100 0 62.1
Piperacillin—tazobactam 100 72.7 75 85.7 100 100 88.9
Tobramycin 100 100 100 100 60 100 93.3
TMP—SMX 9.1 100 100 42.9 80 100 72.0
TMP—SMX: trimethoprim—sulfamethoxazole.documented in the literature. Previous studies of nosocomial
bacteremia in ICU patients report rates of 6.0 and 20.0 per
1000 admissions, however Gram-negative bacteria comprised
only 53% and 11% of the isolated microorganisms, respec-
tively.4,5 Wisplinghoff et al., in an analysis of 24 179 noso-
comial bloodstream cases in a prospective multi-center USA
surveillance study, reported a lower Gram-negative nosoco-
mial bloodstream infection rate of 1.1 per 1000 admissions,
however this included all hospitalized patients, not ICU
patients alone.11 The median time from admission to the
development of bacteremia in our study was 18.5 days.
Wisplinghoff et al. reported shorter mean times from 12 to
26 days in Gram-negative bacteremia.11
The most common organisms isolated were Pseudomonas
aeruginosa and Enterobacter spp. Similar studies of nosoco-
mial Gram-negative bacteremia in critically ill patients have
reported Acinetobacter baumannii,1,12 Pseudomonas,11—13
and Enterobacter14 most commonly. Interestingly, only one
Acinetobacter bacteremia was observed in our study, reflect-
ing the importance of collecting unit-specific data. A large
European single-day point prevalence study of nosocomial
ICU infections, reported Enterobacteriaceae as most com-
mon (34.4%),15 with Pseudomonas second most common
(28.7%). However, only 12% of these infections were bacter-
emias. Regardless, these data emphasize the large number of
nosocomial Gram-negative infections in the critically ill.
The most common source of bloodstream infection in our
study was pneumonia (48.9%) almost all of which was venti-
latorassociated, followedbycentral venouscatheter infection
(22.2%). Previous studies have identified the lower respiratory
tract1 and urinary tract6 as common sources of Gram-negative
bacteremia.While intravenous catheters havebeenpreviously
reported as a leading source of nosocomial bloodstream infec-
tions, the majority of these have been Gram-positive bacter-
emias,11 which were excluded from this study.
Providing epidemiologic data to guide empiric antimicro-
bial therapy is a major goal of this study. Inappropriate
empiric therapy has been shown to predict death in critically
ill patients.16,17 Higher rates of mortality were observed in
patients who received inappropriate empiric antimicrobial
therapy, although the small number of cases limits rigorous
statistical analysis of the role of chance in this finding. In
fact, mortality was 100% in all four cases of bacteremia in
which empiric therapy was not appropriate.
Pseudomonas aeruginosa was relatively fluoroquinolone-
resistant, with only 54.5% susceptibility to ciprofloxacin.Several clinical and pharmacologic studies have suggested
fluoroquinolone monotherapy or combination therapy for the
treatment of ICU infections.18 However, the high risk of
resistance selection is a concern, particularly in ICU, and
is highlighted by our data. Rates of fluoroquinolone resis-
tance among P. aeruginosa are increasing; a recent study
documented an increase from 29% in 1999 to 36% in 2001
associated with increases in hospital and community fluor-
oquinolone use.19 Furthermore, mortality is increased in ICU
patients with P. aeruginosa bacteremia and inadequate anti-
microbial treatment.20 Recent National Nosocomial Infec-
tions Surveillance System (NNIS) data, comparing 1.3
million nosocomial bacterial infections from 1975 to 2003,
indicate that rates of nosocomial infections due to Gram-
negative bacilli are not increasing, but resistance to therapy
is increasing, particularly in Pseudomonas and Acinetobacter
species.21 This issue is particularly concerning given that no
new antibiotics for resistant Gram-negative organisms are
anticipated for at least five years.22
The use of combination antibiotic therapy for Gram-nega-
tive bacteremia is controversial. A recent meta-analysis,
comparing beta-lactam monotherapy with beta-lactam—
aminoglycoside combination therapy for severe infections
found no difference in all-cause fatality (relative risk
0.90, 95% CI 0.77—1.06).23 In addition, there was no advan-
tage among patients with Gram-negative infections or P.
aeruginosa infections. Nephrotoxicity was, however, signifi-
cantly more common with combination therapy.
A second meta-analysis24 reported no overall mortality
benefit with combination therapy; however, analysis of P.
aeruginosa bacteremias alone did show a 50% mortality
benefit. As such, the routine use of combination antibiotic
therapy for Gram-negative bacteremia is not encouraged,
beyond settings where infection by P. aeruginosa is strongly
suspected. If P. aeruginosa is suspected, two-drug coverage
with either an aminoglycoside or ciprofloxacin is recom-
mended. In our unit, gentamicin and tobramycin provide
reliable anti-pseudomonal coverage, but potential nephro-
toxicity is a concern in the critically ill population. Cipro-
floxacin, on the other hand, would provide coverage to
barely half the P. aeruginosa bacteremias in our unit. A
potential compromise might be to give a single dose of
aminoglycoside based on the initial report of Gram-negative
bacteremia, and review treatment in 24—48 hours, when
the identity and antimicrobial susceptibility of the isolate
are available.
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our isolates, highlighting the growing importance of this
nosocomial pathogen.25 Empiric coverage is difficult as few
agents are effective. In our study, isolates were susceptible
only to TMP—SMX. Empiric use of TMP—SMX is problematic in
light of its limited coverage of other organisms, and the large
fluid volume required for administration. In addition, Steno-
trophomonas maltophilia is an organism of low virulence and
rarely a cause of acute clinical deterioration. As such, we do
not recommend empiric TMP—SMX for patients with Gram-
negative bacteremia in our ICU, but the incidence of S.
maltophilia in this population needs to be monitored.
E. coli and Klebsiella can produce extended-spectrum
beta-lactamases (ESBLs). ESBLs are widely prevalent in Latin
America, with rates as high as 32.6% for K. pneumoniae and
11.8% for E. coli in the ICU.26,27 A large international pro-
spective observational study of 12 hospitals identified 30.8%
of all hospital nosocomial bacteremias and 43.5% of episodes
acquired in ICUs were due to ESBL-producing organisms.28 We
did not identify any ESBLs in our study, but these highly
resistant strains may become more widespread in the future.
Minimizing inappropriate antibiotic use, particularly with
beta-lactams containing an oxyimino group,28 may help
guard against the emergence of ESBLs, and is another reason
why these data may help guide clinical decision-making.
SerratiamarcescensandEnterobacter sppwere responsible
for 33.3% of bacteremias. Sensitivity to the third generation
cephalosporins (ceftazidime, cefotaxime, ceftriaxone) was
100% for S. marcescens, and 66.6% for Enterobacter spp.
However, Serratia and Enterobacter spp both have the poten-
tial to carry inducible cephalosporinases. This mandates cau-
tion when using cephalosporins empirically. Despite initial
susceptibility, theseorganismsmayquicklydevelop resistance.
Limitations of this study include the single center design,
small numbers of bacteremia, and a short study period of five
years. Inter-quartile and subset analyses were not possible
due to these limitations.
In summary, this is the first Canadian study of nosocomial
Gram-negative bacteremia in a general ICU. Pseudomonas
aeruginosa and Enterobacter spp were identified as the most
common organisms. Overall sensitivities to imipenem, tobra-
mycin, and gentamicin were statistically superior to ciproflox-
acin, demonstrating significant fluoroquinolone resistance.
Ceftazidime and piperacillin—tazobactam were also highly
active, with no statistically significant difference when com-
pared to imipenem, gentamicin, or tobramycin. The potential
for inducible cephalosporinase production in some organisms,
however, makes ceftazidime a less attractive option for
empiric therapy. If aminoglycosides are to be typically avoided
in critically ill patients due to nephrotoxicity, then imipenem
or piperacillin—tazobactam appear to be the antimicrobials
most appropriate for empiric therapy in our intensive care
unit. Local surveillance data should similarly be used to guide
empiric therapy in other ICUs, and to ensure optimal therapy
and resource allocation in the critically ill.
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